BIOMAT Database Logo BIOMAT Database Logo

Discovery of 2,3-Dihydro[1,4]dioxino[2,3-g]benzofuran Derivatives as Protease Activated Receptor 4 (PAR4) Antagonists with Potent Antiplatelet Aggregation Activity and Low Bleeding Tendency. 2024

Panpan Chen, and Cai Chen, and Yizheng Zheng, and Fangjun Chen, and Zhaojun Liu, and Shenhong Ren, and Hangyu Song, and Tongdan Liu, and Zhipeng Lu, and Hongbin Sun, and Yi Kong, and Haoliang Yuan
Jiangsu Key Laboratory of Drug Discovery for Metabolic Disease, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China.

Patients with arterial embolic disease have benefited greatly from antiplatelet therapy. However, hemorrhage risk of antiplatelet agents cannot be ignored. Herein, we describe the discovery of 2,3-dihydro[1,4]dioxino[2,3-g]benzofuran compounds as novel PAR4 antagonists. Notably, the isomers 36 and 37 with the chemotype of phenoxyl methylene substituted on the 2,3-dihydro-1,4-dioxine ring exhibited potent in vitro antiplatelet activity (IC50 = 26.13 nM for 36 and 14.26 nM for 37) and significantly improved metabolic stability in human liver microsomes (T1/2 = 97.6 min for 36 and 11.1 min for BMS-986120). 36 also displayed good oral PK profiles (mice: T1/2 = 7.32 h and F = 45.11%). Both of them showed overall potent ex vivo antiplatelet activity at concentrations of 6 and 12 mg/kg, with no impact on the coagulation system and low bleeding liability. Our work will facilitate development of novel PAR4 antagonists as a safer therapeutic option for arterial embolism.

UI MeSH Term Description Entries
D010974 Platelet Aggregation The attachment of PLATELETS to one another. This clumping together can be induced by a number of agents (e.g., THROMBIN; COLLAGEN) and is part of the mechanism leading to the formation of a THROMBUS. Aggregation, Platelet
D010975 Platelet Aggregation Inhibitors Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system. Antiaggregants, Platelet,Antiplatelet Agent,Antiplatelet Agents,Antiplatelet Drug,Blood Platelet Aggregation Inhibitor,Blood Platelet Antagonist,Blood Platelet Antiaggregant,PAR-1 Antagonists,Platelet Aggregation Inhibitor,Platelet Antagonist,Platelet Antagonists,Platelet Antiaggregant,Platelet Antiaggregants,Platelet Inhibitor,Protease-Activated Receptor-1 Antagonists,Antiplatelet Drugs,Blood Platelet Aggregation Inhibitors,Blood Platelet Antagonists,Blood Platelet Antiaggregants,Platelet Inhibitors,Agent, Antiplatelet,Aggregation Inhibitor, Platelet,Antagonist, Blood Platelet,Antagonist, Platelet,Antiaggregant, Blood Platelet,Antiaggregant, Platelet,Drug, Antiplatelet,Inhibitor, Platelet,Inhibitor, Platelet Aggregation,PAR 1 Antagonists,Platelet Antagonist, Blood,Platelet Antiaggregant, Blood,Protease Activated Receptor 1 Antagonists
D001777 Blood Coagulation The process of the interaction of BLOOD COAGULATION FACTORS that results in an insoluble FIBRIN clot. Blood Clotting,Coagulation, Blood,Blood Clottings,Clotting, Blood
D001792 Blood Platelets Non-nucleated disk-shaped cells formed in the megakaryocyte and found in the blood of all mammals. They are mainly involved in blood coagulation. Platelets,Thrombocytes,Blood Platelet,Platelet,Platelet, Blood,Platelets, Blood,Thrombocyte
D006470 Hemorrhage Bleeding or escape of blood from a vessel. Bleeding,Hemorrhages
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001572 Benzofurans Compounds that contain a BENZENE ring fused to a furan ring. Coumarones,Diphenylbenzofuran
D013927 Thrombosis Formation and development of a thrombus or blood clot in BLOOD VESSELS. Atherothrombosis,Thrombus,Blood Clot,Blood Clots,Thromboses
D044463 Receptor, PAR-1 A thrombin receptor subtype that couples to HETEROTRIMERIC GTP-BINDING PROTEINS resulting in the activation of a variety of signaling mechanisms including decreased intracellular CYCLIC AMP, increased TYPE C PHOSPHOLIPASES and increased PHOSPHOLIPASE A2. PAR-1 Receptor,Protease-Activated Receptor 1,PAR1 Receptor,Proteinase-Activated Receptor 1,PAR 1 Receptor,Protease Activated Receptor 1,Proteinase Activated Receptor 1,Receptor, PAR 1,Receptor, PAR1

Related Publications

Panpan Chen, and Cai Chen, and Yizheng Zheng, and Fangjun Chen, and Zhaojun Liu, and Shenhong Ren, and Hangyu Song, and Tongdan Liu, and Zhipeng Lu, and Hongbin Sun, and Yi Kong, and Haoliang Yuan
Synthesis of novel 2,3-dihydro-1,4-dioxino[2,3-g]quinoline derivatives as potential antitumor agents.
March 2004, Bioorganic & medicinal chemistry,
Panpan Chen, and Cai Chen, and Yizheng Zheng, and Fangjun Chen, and Zhaojun Liu, and Shenhong Ren, and Hangyu Song, and Tongdan Liu, and Zhipeng Lu, and Hongbin Sun, and Yi Kong, and Haoliang Yuan
Blockade of protease-activated receptor-4 (PAR4) provides robust antithrombotic activity with low bleeding.
January 2017, Science translational medicine,
Panpan Chen, and Cai Chen, and Yizheng Zheng, and Fangjun Chen, and Zhaojun Liu, and Shenhong Ren, and Hangyu Song, and Tongdan Liu, and Zhipeng Lu, and Hongbin Sun, and Yi Kong, and Haoliang Yuan
PAR4 (Protease-Activated Receptor 4): PARticularly Important 4 Antiplatelet Therapy.
February 2018, Arteriosclerosis, thrombosis, and vascular biology,
Panpan Chen, and Cai Chen, and Yizheng Zheng, and Fangjun Chen, and Zhaojun Liu, and Shenhong Ren, and Hangyu Song, and Tongdan Liu, and Zhipeng Lu, and Hongbin Sun, and Yi Kong, and Haoliang Yuan
Synthesis of 2-substituted-2,3- dihydro-1,4-dioxino[2,3-b]pyridine derivatives.
June 2000, Organic letters,
Panpan Chen, and Cai Chen, and Yizheng Zheng, and Fangjun Chen, and Zhaojun Liu, and Shenhong Ren, and Hangyu Song, and Tongdan Liu, and Zhipeng Lu, and Hongbin Sun, and Yi Kong, and Haoliang Yuan
Discovery of Potent and Selective Quinoxaline-Based Protease-Activated Receptor 4 (PAR4) Antagonists for the Prevention of Arterial Thrombosis.
February 2024, Journal of medicinal chemistry,
Panpan Chen, and Cai Chen, and Yizheng Zheng, and Fangjun Chen, and Zhaojun Liu, and Shenhong Ren, and Hangyu Song, and Tongdan Liu, and Zhipeng Lu, and Hongbin Sun, and Yi Kong, and Haoliang Yuan
Discovery of Protease-Activated Receptor 4 (PAR4)-Tethered Ligand Antagonists Using Ultralarge Virtual Screening.
April 2024, ACS pharmacology & translational science,
Panpan Chen, and Cai Chen, and Yizheng Zheng, and Fangjun Chen, and Zhaojun Liu, and Shenhong Ren, and Hangyu Song, and Tongdan Liu, and Zhipeng Lu, and Hongbin Sun, and Yi Kong, and Haoliang Yuan
Protease-Activated Receptor 4 (PAR4): A Promising Target for Antiplatelet Therapy.
February 2018, International journal of molecular sciences,
Panpan Chen, and Cai Chen, and Yizheng Zheng, and Fangjun Chen, and Zhaojun Liu, and Shenhong Ren, and Hangyu Song, and Tongdan Liu, and Zhipeng Lu, and Hongbin Sun, and Yi Kong, and Haoliang Yuan
Design, synthesis and biological evaluation of 7-(aryl)-2,3-dihydro-[1,4]dioxino[2,3-g]quinoline derivatives as potential Hsp90 inhibitors and anticancer agents.
February 2017, Bioorganic & medicinal chemistry,
Panpan Chen, and Cai Chen, and Yizheng Zheng, and Fangjun Chen, and Zhaojun Liu, and Shenhong Ren, and Hangyu Song, and Tongdan Liu, and Zhipeng Lu, and Hongbin Sun, and Yi Kong, and Haoliang Yuan
Discovery of Potent Protease-Activated Receptor 4 Antagonists with in Vivo Antithrombotic Efficacy.
August 2019, Journal of medicinal chemistry,
Panpan Chen, and Cai Chen, and Yizheng Zheng, and Fangjun Chen, and Zhaojun Liu, and Shenhong Ren, and Hangyu Song, and Tongdan Liu, and Zhipeng Lu, and Hongbin Sun, and Yi Kong, and Haoliang Yuan
Protease activated receptor 4 (PAR4) antagonists: Research progress on small molecules in the field of antiplatelet agents.
January 2021, European journal of medicinal chemistry,
Copied contents to your clipboard!